268 filings
Page 4 of 14
8-K
4tkyp2
25 Mar 22
Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results
7:11am
8-K
9ycx87rh xr1dj
28 Feb 22
Results of Operations and Financial Condition
8:16am
8-K
pgd ivbcx
14 Feb 22
Larimar Therapeutics Provides Update on CTI-1601 Clinical Program
12:00am
8-K
ehcyppa7
12 Nov 21
Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results
7:21am
8-K
xbl6y54 4h3wy3x
12 Aug 21
Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results
10:29am
8-K
e9l6u8wjkw057a 8a636
1 Jul 21
Other Events
6:11am
8-K
jbkd 87khom90
14 Jun 21
Other Events
5:21pm
8-K
jtmc498yng29olva3a
26 May 21
Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing
10:17am
8-K
1vwunc32
21 May 21
Entry into a Material Definitive Agreement
9:30am
8-K
bk8th fdcj1n4e
21 May 21
Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia
7:28am
8-K
0xkf58zqfkwozk9zfq7u
18 May 21
Other Events
3:09pm
8-K
2b4sc kv1b
17 May 21
Submission of Matters to a Vote of Security Holders
6:08am
8-K
826zghixd14o6awsjah
11 May 21
Other Events
8:34am
8-K
67hcodrho46e29e
10 May 21
Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results
4:15pm
8-K/A
x3y3x etyh1tm
4 Mar 21
Unaudited Pro Forma Combined Financial Statements
5:16pm